Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Building on its focus on rare and serious diseases, CSL Behring announced Aug. 28 that it was acquiring